SMYD3 and ovarian cancer: Many studies have demonstrated that SMYD3 acts as an oncogene in hepatocellular carcinoma, breast cancer, ovarian cancer, and renal cell carcinoma, in which SMYD3 regulates downstream targets involved in proliferation and metastasis (40–43).